Production of plasmid DNA as a pharmaceutical.
Developments in gene therapy, cell therapy, and DNA vaccination require a pharmaceutical gene vector that, on one hand, fulfils the properties to express the encoded information--preferably at the right place, time, and level and, on the other hand, is safe and productive under good manufacturing practices (GMP). Here we summarize the features of producing and modifying these nonviral gene vectors and ensuring the required quality to treat cells and humans or animals.
Schleef
Martin
M
PlasmidFactory GmbH & Co KG, Bielefeld, Germany.
Blaesen
Markus
M
D004247:DNA / Q000096:biosynthesis*; D005822:Genetic Vectors / Q000235:genetics; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010957:Plasmids / Q000096:biosynthesis*; D014780:Viruses / Q000235:genetics
D004364:Pharmaceutical Preparations; D004247:DNA